31 research outputs found

    Comparison of adverse effects of anti-tumor therapy for breast cancer shortly after COVID-19 diagnosis vs. the control period

    Get PDF
    BackgroundCOVID-19 is an acute infectious disease caused by SARS-CoV-2. The best time to restart antitumor therapy in breast cancer patients after SARS-CoV-2 infection is unknown. This study aimed to evaluate treatment-related adverse events in breast cancer patients who received antitumor therapies within a short time after SARS-CoV-2 infection (observation) as well as before (control) and to provide safety data.MethodsWe conducted a self-controlled cohort study using the data from the Breast Disease Center of Peking University First Hospital. We identified patients who received antitumor therapy within 28 days after COVID-19 infection between December 20, 2022, and January 20, 2023. The primary outcome was treatment-related adverse events. McNemar’s test was used to compare the incidence rate of adverse reactions between periods.ResultsWe identified 183 patients with breast cancer, of whom 109 were infected with SARS-CoV-2 within 28 days before antitumor treatment and were included. In total, 28 patients (25.7%) received neoadjuvant therapy, 60 (55.0%) received adjuvant therapy, and 21 (19.3%) received advanced rescue therapy. None of patients required hospitalization for severe or critical COVID-19, but 15 patients (13.8%) still had sequelae of COVID-19 while receiving antitumor treatment. The most common adverse events were peripheral neuropathy (n = 32 [29.4%]), pain (n = 29 [26.6%]), fatigue (n = 28 [25.7%]), nausea (n = 23 [21.1%]), and neutropenia (n = 19 [17.4%]). There was no increased risk of overall treatment-related adverse events (n = 87 [79.8%] vs. n = 91 [83.5%]; p = 0.42) or serious adverse events (n = 13 [11.9%] vs. n = 12 [11.0%]; p = 1.00) from receiving antitumor therapy shortly after the diagnosis of COVID-19. We also found no increased risk in subgroup analyses, and no patients discontinued antitumor therapy due to adverse events.ConclusionRestarting antitumor therapy 2-4 weeks after having mild or moderate COVID-19 is a relatively safe strategy for breast cancer patients that does not increase the risk of treatment-related adverse events

    The clinicopathological factors associated with disease progression in Luminal a breast cancer and characteristics of metastasis: A retrospective study from a single center in China

    Get PDF
    Background/Aim: This study investigated the clinicopathological factors associated with outcomes in patients with Luminal A breast cancer. Patients and Methods: Retrospective analysis of the association of clinicopathological factors and breast cancer outcome in 421 patients with newly diagnosed Luminal-A breast cancer that were enrolled from January 2008 to December 2014. Clinicopathological data were analyzed to validate the relationship with disease free survival (DFS) and overall survival (OS). Kaplan-Meier curves and log-rank tests were used to analyze the value of clinicopathological factors (tumor size, node status and lymphovascular invasion), and subsequent Cox regression analysis revealed significant prognostic factors. Results: With a median of 61 months follow up, the 5-year DFS and 5-year OS rate were 98.3% and 99.3%. Cox multivariate regression analysis showed that clinical anatomic stage, tumor size, status of lymph nodes, lymphovascular invasion and systemic treatment are strong prognostic factors for clinical outcome in patients with Luminal-A breast cancer. Of all 413 patients with stage I-III breast cancer, 14 presented with metastasis (3.4%) during the follow up. Bone (6/14, 42.9%) was the most common site of metastasis followed by liver (5/14, 35.7%) and lung (4/14, 28.6%). The median survival time after metastasis was 20.4 months. Of all the sites of distant metastasis, liver metastasis was the only factor that affected survival time after metastasis (χ2=6.263, p=0.012). Conclusion: Patients with Luminal A breast cancer have excellent outcomes. Liver metastasis is an important factor compressing the survival time after distant metastasis presents

    Effect of Ammonia Addition on the Ignition Delay Mechanism of Methyl Decanoate

    No full text
    In this study, the effect of mixing a small amount of ammonia on the ignition delay time of methyl decanoate under different conditions was studied from the perspective of the combustion mechanism. The effect of adding ammonia on the ignition delay time of methyl decanoate at different pressures and temperatures was studied by means of simulation calculations and numerical comparison. Integrating the detailed mechanism and reaction path of methyl decanoate, the sensitivity of the ignition delay time was investigated. Analyses of the ignition delay time and rate of production were conducted to explore the transformation and influence of ammonia on the oxidation/decomposition process of the main elementary reaction during the ignition of methyl decanoate. The research illustrated that the ignition delay time of methyl decanoate increased with the number of moles of mixed ammonia at a certain temperature range, and in the negative temperature coefficient region, the effect of ammonia on the ignition delay time was the greatest. In addition, the susceptibility and yield analysis of methyl decanoate showed that the addition of ammonia had a weakening effect on the elementary reactions that originally promoted and inhibited methyl decanoate, and its consumption and production rates were reduced

    Unfolded Coprime Linear Array with Three Subarrays for Non-Gaussian Signals: Configuration Design and DOA Estimation

    No full text
    In this paper, we investigate the problem of sparse array design for the direction of the arrival (DOA) of non-Gaussian signals and exploit the unfolded coprime linear array with three subarrays (UCLATS) to obtain physical sensors location. With the motivation from the large consecutive degree of freedom (DOF), we optimize the process of obtaining physical sensors location from two steps. Specifically, the first is to model the process of obtaining the longest consecutive virtual sum co-array from a given number of physical array elements into a global postage-stamp problem (GPSP), whose solution can be employed to determine the locations of the longest possible consecutive sum co-array (2-SC) and initial physical array. The second step is to multiply the location of the virtual sum co-array by appropriate coprime coefficients to generate UCLATS and then multiply the initial physical array position by the same corresponding coefficients to obtain physical sensors location. Besides, an algorithm is proposed to obtain DOA estimates, which employs the discrete Fourier transform (DFT) method and partial spectrum searching multiple signal classification (PSS-MUSIC) algorithm to obtain initial estimates and fine estimates, respectively, termed as the DFT-MUSIC method. Compared with the traditional total spectrum searching MUSIC (TSS-MUSIC) algorithm, the DFT-MUSIC method performs the same asymptotical performance of DOA estimation with less than 10% complex multiplication times, which can be verified by numerical simulations under the same condition

    Decomposed Driving Factors of Carbon Emissions and Scenario Analyses of Low-Carbon Transformation in 2020 and 2030 for Zhejiang Province

    No full text
    Climate change has gained widespread attention, and the rapid growth of the economy in China has generated a considerable amount of carbon emissions. Zhejiang Province was selected as a study area. First, the energy-related carbon emissions from 2000 to 2014 were accounted for, and then the Logarithmic Mean Divisia Index (LMDI) decomposition model was applied to analyse the driving factors underlying the carbon emissions. Finally, three scenarios (inertia, comparative decoupling and absolute decoupling) for 2020 and 2030 were simulated based on the low-carbon city and Human Impact Population Affluence Technology (IPAT) models. The results showed (1) carbon emissions increased by 1.66 times from 2000 to 2014, and trends of carbon emissions were used to divide the study period into three phases (rapid, medium growth and slow decrease phases, with annual growth rates of 12.60%, 4.77% and −1.24%, respectively); (2) the energy intensity effect from 2000–2011 inhibited carbon emissions but was exceeded by the economic output effect, which increased emissions, whereas the energy intensity effect from 2011–2014 outweighed the economic output effect; (3) the scenario analyses revealed that both the comparative and absolute decoupling scenarios would remain consistent with the carbon emissions boundaries in 2020 and 2030, but the comparative decoupling scenario was more reasonable for sustainable development. In addition, appropriate design of emission trading scheme could help to achieve the comparative decoupling by financial incentives

    Regulatory network analysis of hypertension and hypotension microarray data from mouse model

    No full text
    We aimed to identify the potential genes related to blood pressure regulation and screen target genes for high blood pressure (BPH) and low blood pressure (BPL) treatment. The GSE19817 microarray dataset, which included the aorta, liver, heart, and kidney samples from BPH, BPL, and normotensive mice, was downloaded from the Gene Expression Omnibus. Principal component analysis (PCA) was performed based on the entire expression profile. Differentially expressed genes (DEGs) were screened, followed by pathway enrichment analysis. Finally, gene regulatory networks were constructed based on BPH-related and BPL-related DEGs in the aorta, liver, heart, and kidney samples. As a result, DEGs were screened within their respective tissues due to high heterogeneity of different tissues. Totally, 2,726 BPH-related DEGs and 2,472 BPL-related DEGs were screened, which were mainly enriched in pathways such as immune response. The topology data of gene regulatory networks constructed by DEGs in the heart, kidney, and liver were similar than that in aorta. Finally, among BPH-related DEGs, Sept6 and Pigx were found in the top 10 differentially regulated DEGs by comparing the BPH-related DEGs of the aorta with the DEGs of the other 3 tissues in the regulatory network. Although among the top 10 differentially regulated BPL-related DEGs, no common differentially regulated DEGs were found, Wif1, Urb2, and Gtf2ird1 were found among the top ten DEGs in the three tissues other than the kidney tissue. Sept6 and Pigx might participate in the pathogenesis of BPH, whereas Gtf2ird1, Urb2, and Wif1 might be critical target genes for BPL treatment

    Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy

    No full text
    (1) Background: Neoadjuvant therapy is the main therapeutic strategy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, and the combination of trastuzumab and pertuzumab (HP) has become a routine treatment. How to predict and screen patients who are less likely to respond to neoadjuvant therapy is the focus of research. The androgen receptor (AR) is a biomarker that is widely expressed in all breast cancer subtypes and is probably related to treatment response and prognosis. In this study, we investigated the relationship between AR expression and treatment response in HER2-positive breast cancer patients treated with HP neoadjuvant therapy. (2) Methods: We evaluated early breast cancer patients treated with HP neoadjuvant therapy from Jan. 2019 to Oct. 2020 at Peking University First Hospital Breast Cancer Center. The inclusion criteria were as follows: early HER2-positive breast cancer patients diagnosed by core needle biopsy who underwent both HP neoadjuvant therapy and surgery. We compared the clinical and pathological features between pathological complete response (pCR) and non-pCR patients. (3) Results: We included 44 patients. A total of 90.9% of patients received neoadjuvant therapy of taxanes, carboplatin, trastuzumab and pertuzumab (TCHP), and the total pCR rate was 50%. pCR was negatively related to estrogen receptor (ER) positivity (OR 0.075 [95% confidence interval (CI) 0.008–0.678], p = 0.021) and positively related to high expression levels of AR (OR 33.145 [95% CI 2.803–391.900], p = 0.005). We drew a receiver operating characteristic (ROC) curve to assess the predictive value of AR expression for pCR, and the area under the curve was 0.737 (95% CI 0.585–0.889, p = 0.007). The optimal cutoff of AR for predicting pCR was 85%. (4) Conclusion: AR is a potential marker for the prediction of pCR in HER2-positive breast cancer patients treated with HP neoadjuvant therapy

    Table_1_To diagnose primary and secondary squamous cell carcinoma of the thyroid with ultrasound malignancy risk stratification.docx

    No full text
    ObjectivesThis study aimed to investigate the clinico-ultrasound features of primary squamous cell carcinoma of the thyroid (PSCCT) and secondary SCCT (SSCCT) and evaluate the accuracy of fine needle aspiration (FNA) recommendation for SCCT with American College of Radiology-Thyroid Imaging and Reporting Data System (ACR-TIRADS) and Chinese-TIRADS (C-TIRADS).Materials and methodsWe retrieved 26 SCCT patients (11 PSCCT, 15 SSCCT) from our hospital’s pathology database (5,718 patients with thyroid malignancy) over 23 years. Medical records and ultrasound data of the 26 patients with 27 SCCTs were analyzed retrospectively, and each SCCT focus was categorized based on the two TIRADSs.ResultsFor 26 patients (21 males, 5 females) with an age range of 42-81 years, rapidly enlarging thyroid/neck nodules (18/26, 69.2%), dysphagia (7/26, 26.9%), hoarseness (6/26, 23.1%), dyspnea (5/26, 19.6%), cough (4/26, 15.4%), neck pain (2/26, 7.7%), B symptoms (2/26, 7.7%), and blood in sputum (1/26, 3.8%) were presented at diagnosis. Five asymptomatic patients (5/26, 19.2%) were detected by ultrasound. Hoarseness was more common in PSCCT (5/11, 45.5%) than in SSCCT (1/15, 6.7%) (P=0.032). For 27 SCCTs with a mean size of 3.7 ± 1.3 cm, the ultrasound features consisted of solid (25/27, 92.6%) or almost completely solid composition (2/27, 7.4%), hypoechoic (17/27, 63%) and very hypoechoic echogenicity (10/27, 37%), irregular/lobulated margin with extra-thyroidal extension (27/27, 100%), taller-than-wide shape (13/27, 48.1%), punctate echogenic foci (6/27, 22.2%), hypervascularity (23/27, 85.2%) and involved neck lymph (13/26, 50.0%). A total of 27 SCCTs were evaluated as high malignancy risk stratification (≥TR4 and 4B) by the two TIRADSs and recommended FNA in 96.3–100% (26/27, 27/27). Pathologically, more than half of PSCCTs (7/12, 58.3%) and a quarter of SSCCTs (4/15, 26.7%) were poorly differentiated, while moderately and well-differentiated grades were observed in 5 PSCCTs and 11 SSCCTs (P=0.007). Thirteen patients (50.0%) underwent surgery with radical operation in 5 cases (5/13, 38.5%).ConclusionSCCT is an extremely rare and aggressive malignancy with a male predominance. PSCCT and SSCCT had similar clinical and ultrasound features except for tumor differentiation and the symptom of hoarseness. SCCT showed a high malignancy risk stratification in ACR-TIRADS and C-TIRADS, with a high rate of FNA recommendation.</p

    Integrative analysis identifies cancer cell-intrinsic RARRES1 as a predictor of prognosis and immune response in triple-negative breast cancer

    No full text
    Triple-negative breast cancer (TNBC) is a subtype of breast cancer with poor prognosis and limited treatment options. Although immune checkpoint inhibitors (ICIs) have been proven to improve outcomes in TNBC patients, the potential mechanisms and markers that determine the therapeutic response to ICIs remains uncertain. Revealing the relationship and interaction between cancer cells and tumor microenvironment (TME) could be helpful in predicting treatment efficacy and developing novel therapeutic agents. By analyzing single-cell RNA sequencing dataset, we comprehensively profiled cell types and subpopulations as well as identified their signatures in the TME of TNBC. We also proposed a method for quantitatively assessment of the TME immune profile and provided a framework for identifying cancer cell-intrinsic features associated with TME through integrated analysis. Using integrative analyses, RARRES1 was identified as a TME-associated gene, whose expression was positively correlated with prognosis and response to ICIs in TNBC. In conclusion, this study characterized the heterogeneity of cellular components in TME of TNBC patients, and brought new insights into the relationship between cancer cells and TME. In addition, RARRES1 was identified as a potential predictor of prognosis and response to ICIs in TNBC
    corecore